Pfizer and BioNTech have secured another opportunity to contest the validity of one of Moderna’s mRNA vaccine patents. This development follows a judge’s decision on Wednesday, highlighting that their appeal had a reasonable prospect of success. This is a significant move in the ongoing intellectual property battle between the pharmaceutical giants regarding mRNA technology, which has been pivotal in the fight against COVID-19.
More details on the ruling and its implications for the future of mRNA vaccine litigation can be found in the report by Law360.